StoneX Group’s bioAffinity Technologies BIAF Stock Holding History

StoneX Group’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-507	Closed	-$4.37K	–	940
2025 Q2	$4.37K	Buy	+507	New	+$5.8K	﹤0.01%	850

Other funds holding BIAF

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

LFG

Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return

StoneX Group's BIAF Position: Q3 2025 in Review

StoneX Group sold out of bioAffinity Technologies (BIAF) in Q3 2025, closing a stake of 507 shares — an estimated $4.37K sold.

StoneX Group first reported a position in BIAF in Q2 2025 and held it in 1 quarter. The position peaked at $4.37K in Q2 2025. 12 funds tracked by Wall St. Rank hold BIAF as of Q3 2025.

StoneX Group reported no remaining bioAffinity Technologies position as of Q3 2025 after selling out during the quarter.
StoneX Group sold 507 bioAffinity Technologies shares in Q3 2025, an estimated $4.37K.
StoneX Group first reported a position in bioAffinity Technologies in Q2 2025 and held it in 1 quarter.
StoneX Group's bioAffinity Technologies position peaked at $4.37K in Q2 2025.
12 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q3 2025.

Based on StoneX Group's 13F filing for Q3 2025, filed 14 Nov 2025.